SYL1801 is a chemically modified siRNA, engineered using Sylentis’ proprietary SirFinder™, in Phase II clinical research for the prevention and/or control of the progression of wet age-related macular degeneration (AMD).
SYL1801 is administered as an eye drop solution to transcriptionally down-regulate the expression of Nrarp, a target different from those against which the usual anti-angiogenic therapies based on anti-VEGF agents are directed.
SYL1801 inhibits the synthesis of Nrarp, which plays an important role in controlling the formation of new blood vessels in the retina.
Macular degeneration is a degenerative condition of a central part of the retina known as the macula, which is responsible for central vision. That is, this area of the eye allows fine vision tasks such as recognizing faces, reading or sewing.
- AMD is the leading cause of irreversible visual impairment in the elderly population of developed countries.
- Currently, treatment of AMD involves periodic intraocular injections of antiangiogenic drugs.
- The development of drugs that are administered by noninvasive
routes is an unmet medical need for this type of patient.
Blurred vision, the appearance of black spots in the central area of the visual field and distorted or wavy perception of straight lines are the main symptoms of this disease.
At present, AMD can be controlled by the use of anti-angiogenic drugs administered by periodic intraocular injections. The development of drugs administered in drops would mean a substantial improvement in the quality of life of patients.